Want to see BVS full AI Analyst Report?
Total Valuation
Bioventus has a market cap or net worth of $1.21B. The enterprise value is $976.20.
Market Cap$1.21B
Enterprise Value$976.20
Share Statistics
Bioventus has 68,305,145 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,305,145
Owned by Insiders31.86%
Owned by Institutions47.98%
Financial Efficiency
Bioventus’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.79%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)10.79%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee597.99K
Profits Per Employee0.00
Employee Count950
Asset Turnover0.83
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Bioventus is 17.9. Bioventus’s PEG ratio is -0.13.
PE Ratio17.9
PS Ratio0.87
PB Ratio2.69
Price to Fair Value2.69
Price to FCF6.94
Price to Operating Cash Flow10.07
PEG Ratio-0.13
Income Statement
In the last 12 months, Bioventus had revenue of 568.09M and earned 22.73M in profits. Earnings per share was 0.34.
Revenue568.09M
Gross Profit382.43M
Operating Income58.55M
Pretax Income25.71M
Net Income22.73M
EBITDA99.21M
Earnings Per Share (EPS)0.34
Cash Flow
In the last 12 months, operating cash flow was 96.87M and capital expenditures -2.59M, giving a free cash flow of 94.29M billion.
Operating Cash Flow96.87M
Free Cash Flow94.29M
Free Cash Flow per Share1.38
Dividends & Yields
Bioventus pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change93.28%
50-Day Moving Average11.86
200-Day Moving Average9.38
Relative Strength Index (RSI)61.78
Average Volume (3m)654.88K
Important Dates
Bioventus upcoming earnings date is Nov 10, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Bioventus as a current ratio of 1.70, with Debt / Equity ratio of 115.52%
Current Ratio1.70
Quick Ratio1.19
Debt to Market Cap0.60
Net Debt to EBITDA2.62
Interest Coverage Ratio2.21
Taxes
In the past 12 months, Bioventus has paid -1.56M in taxes.
Income Tax-1.56M
Effective Tax Rate-0.06
Enterprise Valuation
Bioventus EV to EBITDA ratio is 7.62, with an EV/FCF ratio of 10.58.
EV to Sales1.33
EV to EBITDA7.62
EV to Free Cash Flow10.58
EV to Operating Cash Flow10.22
Balance Sheet
Bioventus has $29.46M in cash and marketable securities with $263.75M in debt, giving a net cash position of -$234.29M billion.
Cash & Marketable Securities$29.46M
Total Debt$263.75M
Net Cash-$234.29M
Net Cash Per Share-$3.43
Tangible Book Value Per Share-$2.21
Margins
Gross margin is 68.00%, with operating margin of 10.31%, and net profit margin of 4.00%.
Gross Margin68.00%
Operating Margin10.31%
Pretax Margin4.53%
Net Profit Margin4.00%
EBITDA Margin17.46%
EBIT Margin9.19%
Analyst Forecast
The average price target for Bioventus is $18.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.33
Price Target Upside55.37% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast3.14%
EPS Growth Forecast―